Genetic Modifiers of Cystic Fibrosis–Related Diabetes

Scott M. Blackman(Johns Hopkins University), Clayton W. Commander(University of North Carolina at Chapel Hill), Chris Watson(Johns Hopkins University), Kristin M. Arcara(Johns Hopkins University), Lisa J. Strug(University of Toronto), Jaclyn R. Stonebraker(University of North Carolina at Chapel Hill), Fred A. Wright(University of North Carolina at Chapel Hill), Johanna M. Rommens(University of Toronto), Lei Sun(University of Toronto), Rhonda G. Pace(University of North Carolina at Chapel Hill), Sarah A. Norris(University of North Carolina at Chapel Hill), Peter R. Durie(University of Toronto), Mitchell L. Drumm(Pediatrics and Genetics), Michael R. Knowles(University of North Carolina at Chapel Hill), Garry R. Cutting(Johns Hopkins University)
Diabetes
May 14, 2013
Cited by 174Open Access
Full Text

Abstract

Diabetes is a common age-dependent complication of cystic fibrosis (CF) that is strongly influenced by modifier genes. We conducted a genome-wide association study in 3,059 individuals with CF (644 with CF-related diabetes [CFRD]) and identified single nucleotide polymorphisms (SNPs) within and 5' to the SLC26A9 gene that associated with CFRD (hazard ratio [HR] 1.38; P = 3.6 × 10(-8)). Replication was demonstrated in 694 individuals (124 with CFRD) (HR, 1.47; P = 0.007), with combined analysis significant at P = 9.8 × 10(-10). SLC26A9 is an epithelial chloride/bicarbonate channel that can interact with the CF transmembrane regulator (CFTR), the protein mutated in CF. We also hypothesized that common SNPs associated with type 2 diabetes also might affect risk for CFRD. A previous association of CFRD with SNPs in TCF7L2 was replicated in this study (P = 0.004; combined analysis P = 3.8 × 10(-6)), and type 2 diabetes SNPs at or near CDKAL1, CDKN2A/B, and IGF2BP2 were associated with CFRD (P < 0.004). These five loci accounted for 8.3% of the phenotypic variance in CFRD onset and had a combined population-attributable risk of 68%. Diabetes is a highly prevalent complication of CF, for which susceptibility is determined in part by variants at SLC26A9 (which mediates processes proximate to the CF disease-causing gene) and at four susceptibility loci for type 2 diabetes in the general population.


Related Papers